Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sinopharm Tech Holdings's Enterprise Value is HK$211.18 Mil.
Sinopharm Tech Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-2.93 Mil. Therefore, Sinopharm Tech Holdings's EV-to-FCF for today is -72.12.
The historical rank and industry rank for Sinopharm Tech Holdings's EV-to-FCF or its related term are showing as below:
HKSE:08156'
s EV-to-FCF Range Over the Past 10 Years
Min: -74.53 Med: -26.75 Max: 2691.73
Current: -72.12
During the past 13 years, the highest EV-to-FCF of Sinopharm Tech Holdings was 2691.73. The lowest was -74.53. And the median was -26.75.
HKSE:08156's EV-to-FCF is ranked worse than 100% of 1597
companies
in the Software industry
Industry Median: 15.63
vs HKSE:08156: -72.12
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sinopharm Tech Holdings's PE Ratio (TTM) for today is calculated as:
Sinopharm Tech Holdings's share price for today is HK$0.156.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinopharm Tech Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:08156 vs QH, SHOP, UBER: EV-to-FCF Comparison
For the Software - Application subindustry, Sinopharm Tech Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Tech Holdings EV-to-FCF vs Software Industry
For the Software industry and Technology sector, Sinopharm Tech Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sinopharm Tech Holdings's EV-to-FCF falls into.
Sinopharm Tech Holdings's current Enterprise Value is HK$211.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinopharm Tech Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-2.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Tech Holdings (HKSE:08156) has a EV-to-FCF of -72.12 as of Aug. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sinopharm Tech Holdings and its competitors. According to the industry distribution chart, Sinopharm Tech Holdings ranks #999999 out of 1597 companies in the Software industry.
Is Sinopharm Tech Holdings' EV-to-FCF too high?
Sinopharm Tech Holdings' current EV-to-FCF is -72.12. Based on the distribution chart, Sinopharm Tech Holdings ranks #999999 out of 1597 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Sinopharm Tech Holdings has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Tech Holdings' EV-to-FCF compare to QH and SHOP?
According to the Software industry distribution chart, Sinopharm Tech Holdings ranks #999999 out of 1597 companies for EV-to-FCF. This places Sinopharm Tech Holdings in the lower half of its industry. The industry median EV-to-FCF is 15.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Software company?
The median EV-to-FCF among Software companies is 15.63, based on 1,597 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sinopharm Tech Holdings and its competitors. For the Software industry, the median EV-to-FCF is 15.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Tech Holdings's current EV-to-FCF is -72.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Tech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Tech Holdings (HKSE:08156) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.06, compared to a current price of HK$0.16 — trading 160% above its estimated fair value. The current EV-to-FCF is -72.12. Sinopharm Tech Holdings' overall GF Score™ is 27/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sinopharm Tech Holdings (HKSE:08156), the current EV-to-FCF is -72.12 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Tech Holdings (HKSE:08156) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Tech Holdings stock appears to be overvalued.
The current stock price of HK$0.16 is trading 160% above its estimated GF Value™ of HK$0.06.
GuruFocus considers Sinopharm Tech Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:08156:
EV-to-FCF: -72.12
GF Value™: HK$0.06 vs. price of HK$0.16 (160% above fair value)
No single metric tells the full story. See the HKSE:08156 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinopharm Tech Holdings Ltd is an investment holding company operating through three segments: Internet Plus services, Supply Chain services, and Manufacturing and distribution of personal protective equipment. The company generates the majority of its revenue from the Supply Chain services segment, which includes supply chain management, data analysis, and trading of medical and related products. Geographically, it operates in Hong Kong and the People's Republic of China (PRC), with the majority of its revenue coming from the PRC.
27GF Score
Get the complete analysis for HKSE:08156
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08156 has been successfully added to your 
